Holen Sie sich die Stockscreener-App
29.76
4.03%
-1.25
Handel nachbörslich:
30.19
0.43
+1.44%
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Stock Market Today, April 21: Hims & Hers Health Drops as Amazon Unveils Competing Weight Loss Program - Yahoo Finance
Amazon Launches GLP-1 Weight Loss Program with One Medical - GuruFocus
HIMS Stock On Track To Fall For The First Time In Seven Sessions – Why Is Amazon’s GLP-1 Program In The Spotlight? - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Why Is Hims & Hers Health Stock Falling Tuesday?Hims & Hers Health (NYSE:HIMS) - Benzinga
Did Amazon Just Wreck All of Hims & Hers Upside Potential? - Yahoo Finance
Hims & Hers Builds Scalable Data-Driven Personalized Care Platform - Yahoo! Finance Canada
(HIMS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Hims & Hers Health stock falls after Amazon launches GLP-1 program - Investing.com Canada
Hims & Hers (HIMS) Stock Up 49% in Five Days on FDA Peptide Review and Novo Nordisk Deal - CoinCentral
3 Stocks That May Be Trading Below Their Estimated Intrinsic Value - simplywall.st
Hims & Hers Health Shares Surge 48 Percent Ahead of Earnings Report - HarianBasis.co
Significant Bullish Momentum for Hims and Hers Health (HIMS) - GuruFocus
Hims & Hers Health Inc (HIMS) Stock Up 7.6% and Still Undervalued -- GF Score: 81/100 - GuruFocus
Hims & Hers CFO Okupe Oluyemi sells $1.46 million in company stock - Investing.com
Hims & Hers (HIMS) CFO sells 54,927 shares under 10b5-1 plan - Stock Titan
HIMS (HIMS) insider sale notice: 4,651 and 4,812 Class A shares listed - Stock Titan
Hims & Hers Surges Ahead of Earnings as Omnicell Lags in Healthcare Tech Shakeout - TechStock²
Hims & Hers Health stock price forecast: $28.50–$31.80 range as HIMS climbs 4.68% - Traders Union
Why Hims & Hers Health Stock Is Surging Monday - Benzinga
Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal - AOL.com
Cheap Weight-Loss Drugs Are Great — When They're Legal - Bloomberg.com
Novo Deal, Eucalyptus Acquisition, FDA Peptides: Three Catalysts Reshaping Hims & Hers in 2026 - TIKR.com
Hims shares rise as US moves to ease peptide regulations - Global Cosmetics News
Hims & Hers powers patient-provider connectivity via digital platforms - MSN
Hims & Hers (HIMS) Jumps 48% Ahead of Earnings - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Hims & Hers Health, Inc. (HIMS) And Encourages Stockholders to Reach Out - ACCESS Newswire
2026-04-19 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Hims & Hers Health, Inc. (HIMS) And Encourages Stockholders to Reach Out | NYSE:HIMS | Press Release - Stockhouse
Hims & Hers May Have Just Rewritten Its Entire Business Model! - Smartkarma
Healthcare Technology Q4 2025 Report: Sector Revenue Beat & Stock SurgeNews and Statistics - IndexBox
Hims & Hers expands personalized digital healthcare platform - MSN
Hims & Hers Health Inc (HIMS) Stock Price, Quote, News & History - Benzinga
Weekly Market Update: Stocks Gain 4.62% to Hit New All-Time High as Tech Rises, Energy Falls - Morningstar
Hims & Hers Health, Inc. (NYSE:HIMS) Sees Large Drop in Short Interest - MarketBeat
HIMS Stock | Hims & Hers Health Price, Quote, News & Analysis - TipRanks
HIMS Receives Upgrade Amid Positive Regulatory Outlook - GuruFocus
7 Health Care Stocks Whale Activity In Today's Session - Benzinga
Is It Time To Reassess Hims & Hers Health (HIMS) After The Recent Share Price Surge - Yahoo Finance
SA analyst upgrades/downgrades: NVDA, VZ, MRVL, HIMS - Seeking Alpha
Hims & Hers Stock Surges 13% on FDA Peptide Review Optimism and Telehealth Momentum - International Business Times Australia
+7.34% for Hims & Hers Health stock as FDA eyes peptide drug policy change - Traders Union
What's Going On With Hims & Hers Shares - Benzinga
Here’s How Cedar Grove Capital Management Benefitted from Its Short Position in Hims & Hers Health (HIMS) - Yahoo Finance
Hims & Hers stock rises 14% as FDA schedules peptide compounding review - Yahoo Finance
Hims & Hers Health (HIMS) Soars 11.1%: Is Further Upside Left in the Stock? - Yahoo Finance
Hims Hers Health Surprise Signals New Healthcare Momentum Shift Ahead - Kalkine Media
Investor relations - HIMS Investor Relations
HIMS Stock's Rally May Have Plenty Of Room Left: FDA Opens Door To Testosterone Therapy - Stocktwits
HIMS Stock Closes Another Day In The Green — But Retail Sees More Upside - Stocktwits
Why Is HIMS Stock Surging More Than 11% After-Hours Today? - Stocktwits
Q4 Earnings Outperformers: Hims & Hers Health (NYSE:HIMS) And The Rest Of The Healthcare Technology Stocks - Yahoo Finance
Hims & Hers to partner with Novo Nordisk and stop selling compounded GLP-1s - AOL.com
HIMS Stock Rises 7% on Potential FDA Regulatory Changes - GuruFocus
Eli Lilly's Oral Drug Clears CV Test, Hims Surges 14% - Gotrade
Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies - Yahoo Finance
These Stocks Are Today’s Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More - Barron's
Hims & Hers Health (HIMS) Jumps 6.6% to $26.03 - AlphaStreet
Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions - TechStock²
What's Going On With Hims & Hers Stock Thursday - GuruFocus
RFK Jr. Just Gave Hims & Hers Stock a Jolt. Should You Chase the Rally Here? - Barchart
Best Healthcare Stocks To Watch NowApril 16th - MarketBeat
Hims & Hers shares jump as FDA begins review of restricted peptide compounds - Yahoo! Finance Canada
HIMS: Positive Regulatory Developments Boost Stock Outlook - GuruFocus
Leerink reiterates Hims and Hers stock rating on peptide outlook - Investing.com
Hims & Hers Stock: How RFK Jr Loosened Peptide Regulations and Sent Shares Higher - Barron's
HIMS Stock Surges as FDA Plans Review on Peptide Compounding - GuruFocus
Hims rises as FDA considers broader peptides access; analysts see long-term win - Reuters
Hims & Hers (HIMS) Stock; Climbs 8% as FDA Peptide Review Sparks Expansion Hopes - CoinCentral
BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming? - AOL.com
HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell? - The Globe and Mail
2.44%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):